Search clinical trials for: IL-2 Immunotherapy

Total 68571 results

Beijing YouAn Hospital

Unknown

Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC

Hepatocellular Carcinoma

China
Sheba Medical Center

Unknown

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Metastatic Ovarian Cancer

Israel
St. Jude Children's Research Hospital
CURE Childhood Cancer, Inc.

Completed

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (IL2 for GVHD)

Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | AML | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Disorder | ALL | Non-malignant Diseases Requiring Allogeneic HSCT

United States
Stanley H. Appel, MD

Unknown

T-Regulatory Cells in Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis)

United States
Beijing YouAn Hospital

Unknown

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Hepatocellular Carcinoma

China
Masonic Cancer Center, University of Minnesota

Completed

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Stage IV Melanoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

T-Cell Depleted Double UCB for Refractory AML

Acute Myelogenous Leukemia | Refractory Acute Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Myelodysplastic Syndromes | Leukemia

United States
Masonic Cancer Center, University of Minnesota
Miltenyi Biomedicine GmbH

Withdrawn

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

Acute Myelogenous Leukemia

United States
Cytovia, Inc.
EpiCept Corporation

Completed

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Acute Myeloid Leukemia

Sweden
Inge Marie Svane

Completed

TIL Therapy for Metastatic Ovarian Cancer

Metastatic Ovarian Cancer

Denmark
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

Graft-Versus-Host-Disease

United States
St. Jude Children's Research Hospital

Terminated

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Myeloid Sarcoma | Chronic Myelogenous Leukemia (CML) | Non-Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)

United States
Peking University People's Hospital

Terminated

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Leukemia

China
The Methodist Hospital Research Institute
Genentech, Inc.

Terminated

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Carcinoma, Renal Cell

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Women With Stage IV Breast Cancer

Breast Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

HIV Infections

Canada
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH); Chiron...

Completed

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)

Completed

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Melanoma | Skin Cancer

United States
M.D. Anderson Cancer Center

Completed

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma (BCAA)

Melanoma

United States
National Cancer Institute (NCI)

Completed

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Chiron Corporation

Completed

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

Kidney Cancer

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Withdrawn

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells (CLONTAK)

CHRONIC LYMPHOCYTIC B-LEUKEMIA
Endocyte

Terminated

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
Italian Trial in Medical Oncology

Completed

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) (ROSORC)

Renal Cell Carcinoma | Metastatic Disease

Italy
Anaveon AG

Terminated

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Hematologic Diseases | Multiple Myeloma | Refractory Multiple Myeloma | Adult Disease | Relapsed Cancer

Spain, Germany, France, Denmark, Switzerland
Century Therapeutics, Inc.

Not yet recruiting

A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) (CALiPSO-1)

Systemic Lupus Erythematosus
University of Texas Southwestern Medical Center
Prometheus Laboratories

Completed

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

United States
Anaveon AG

Recruiting

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Advanced Solid Tumor | Metastatic Melanoma | Melanoma (Skin) | Cutaneous Melanoma | Adult Disease

United States, Spain, Germany, France, Italy
Werewolf Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Squamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung Cancer

United States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
Anaveon AG

Recruiting

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer. (ANV419-001)

Lung Cancer | Advanced Solid Tumor | Adult Disease

United Kingdom, Switzerland, Spain
Tel-Aviv Sourasky Medical Center
KU Leuven; Michael J. Fox Foundation for Parkinson's Research

Completed

Digital Wearable Walking Aid for Freezing of Gait in Parkinson´s Disease

Parkinson Disease

Israel, Belgium
Leiden University Medical Center
Karolinska Institutet; Children's Investment Fund Foundation; Women on Waves

Not yet recruiting

Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive (WOMEN)

Female Contraception

Netherlands
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
TCRCure Biopharma Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Peking Union Medical College Hospital

Not yet recruiting

Characterizing Histiocytosis With 68Ga-FAPI PET/CT

Histiocytosis

China
BGI, China
Wuhan Union Hospital, China

Recruiting

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Solid Tumor

China
Fujian Cancer Hospital

Not yet recruiting

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Solid Tumors
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Metastatic Solid Tumor

Search clinical trials for: IL-2 Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations